SOLICITATION NOTICE
68 -- GeneArt® Lentiviral CIRSPR Arrayed Kinase Library and GeneArt® Lentiviral Arrayed Cas9 Library
- Notice Date
- 9/11/2015
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA(SSSA)-2015-CSS-821
- Archive Date
- 10/3/2015
- Point of Contact
- Samantha A. Kelly, Phone: 3014028855
- E-Mail Address
-
samantha.kelly2@nih.gov
(samantha.kelly2@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Combined Synopsis / Solicitation Title: GeneArt® Lentiviral CIRSPR Arrayed Kinase Library and GeneArt® Lentiviral Arrayed Cas9 Library (i)This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)The solicitation number is HHS-NIH-NIDA(SSSA)-2015-CSS-821 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. (iii)The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-84, dated September 3, 2015. (iv)This acquisition is unrestricted, open market competition. The associated NAICS code 325414 - Biology Product Manufacturing and the small business size standard is 500 Employees. (v)CRISPR Reagents for the Trans-NIH RNAi CRISPR Initiative (vi)Background The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Center for Advancing Translational Sciences (NCATS) - one of 27 Institutes and Centers at the National Institutes of Health (NIH) - was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster. The NCATS mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. The NCATS is tasked with conducting genome-wide siRNA screens in collaboration with NIH intramural investigators. This work includes RNAi assay development, screening and initial follow-up. The libraries are needed to facilitate the RNAi screening program. Specifically, they will be used to compare the activity of the kinome library against active gene hits identified from primary siRNA screens using the same assays. The CRISPR reagents are being used to validate and follow up on RNAi hits from previous well vetted screens. The CRISPR will be used to complement RNAi screens. Purpose The purpose of this acquisition is to purchase the GeneArt® Lentiviral Arrayed Kinase Library and the GeneArt® Lentiviral Arrayed Cas 9 Library on a brand name or equal basis. Project Requirements The GeneArt® Lentiviral CIRSPR Arrayed Kinase Library (or brand name equal) and GeneArt® Lentiviral Arrayed Cas9 Library (or brand name equal) will be used to confirm active gene hits identified from primary siRNA screens using the same assays. This is vital to help increase confidence in actives. The GeneArt® Lentiviral CIRSPR Arrayed Kinase Library (or brand name equal) and GeneArt® Lentiviral Arrayed Cas9 Library (or brand name equal) must meet the following requirements: 1.Contractor must provide an arrayed lentiviral guide particles with guide per well that will help with arrayed careening. 2.Contractor must provide an arrayed CIRSPR without the use of lentiviral vectors or plasmids to corroborate and complement siRNA screen data. 3.Contractor must provide an arrayed format as synthetic guides. 4.Contractor shall develop and screen the assay and follow up with NCATS on the procedures and results. The following specifications are required: 1.GeneArt® Lentiviral Arrayed Kinase Library (or brand-name equal) •Contractor must provide up to 200 uL of each GeneArt® Lentiviral Arrayed Kinase Particles (or brand-name equal). •Contractor must provide the respective plate maps and clone information. •Contractor must provide a lentivirus spot titer via antibiotic selection and GFP percentages on HT1080 cell lines in a 96-well format, or p24 measurement by ELISA. 2.GeneArt® Lentiviral Arrayed Cas9 Library (or brand-name equal) •Contractor must provide the GeneArt® Lentiviral Arrayed Cas9 Particles (or brand name equal). •Contractor must provide the respective plate maps and clone information. •Contractor must provide a lentivirus titer via antibiotic selection, GFP percentages on HT1080 cell lines in a 96-well format, or p24 measurement by ELISA. Anticipated Period of Performance and Place of Delivery: Delivery is anticipated within thirty days after receipt of the purchase order; period of performance will be defined upon award. (viii)The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix)The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a)The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered, to include past performance. The technical factors together shall be considered more important than price. The Government intends to issue an award on a firm fixed price Contract for this requirement. The technical evaluation factors are as follows, in order of importance: Evaluation Criteria: 1.Factor 1: Technical Approach The Offeror shall detail in its technical proposal how it shall meet each of the project requirements. This shall include the specifications of the offered equipment, specifically if and how it is equal-to-brand name quotation. 2.Factor 2: Delivery The Offeror shall detail in its technical proposal how it shall meet the delivery requirements. The Government shall particularly evaluate ability to meet or exceed delivery schedule requirements. Quotations must include a delivery lead time. (b)Award Criteria Selection of an Offeror for the award will be on the basis of best value, technical factors and price considered. Technical acceptability includes an evaluation on technical factors (which encompasses experience/capability and past performance factors), and cost/price factors. Evaluation of technical acceptability will be made in accordance with the prospective Contractor's demonstrated capabilities of meeting each of the requirements as set forth in this solicitation and all applicable attachments. The merits of each proposal will be evaluated carefully. Offerors must include all specifications/services (including all brand-name or equal requirements so that the brand-name or equal status may be verified), detailed in this solicitation, in its proposal and must also include delivery lead time. Offerors cost/price proposal will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. A redacted invoice, from the current year, for similar requirements or a published price list is requested to determine price reasonableness. The prices quoted will be evaluated taking into consideration any price reductions. A best value analysis will be performed taking into consideration the results of the technical evaluation and price evaluation. (x)The provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items, applies to this acquisition. (xi)FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. An addendum to FAR clause 52.212-4, Contract Terms and Conditions-Commercial Items applies to this acquisition. (xii)FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. (xiv)The Defense Priorities and Allocations System (DPAS) are not applicable to this (xv)Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description, the total cost; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Responses to this solicitation must include clear and convincing evidence of the offerors' capability of fulfilling the requirement as it relates to the technical evaluation criteria and a price proposal. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. Questions regarding this combined synopsis/solicitation must be received in this office by 8:00AM (EST) on September 15, 2015. Offers must be received electronically by 8:00 AM (EST) on September 18, 2015. Facsimile submissions are not authorized and collect calls will not be accepted. Submit offers to: Samantha Kelly, Contract Specialist at Samantha.Kelly2@nih.gov Please reference the solicitation number HHS-NIH-NIDA-(SSSA)-CSS-15-821 on your offer. Requests for information concerning this requirement are to be addressed to Samantha Kelly via e-mail only to Samantha.Kelly2@nih.gov prior to the closing date for questions.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA(SSSA)-2015-CSS-821/listing.html)
- Record
- SN03883380-W 20150913/150912000658-fa4f1fee340bbf96a4f048796410bd9f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |